World leaders in their fields
To drive the development of Apta-1 in the most cost-effective manner, while keeping set schedules, Aptahem collaborates with various consultants and contract research laboratories around the world. Aptahem’s partners are world leaders in their fields, and they meet the, Good Laboratory Practice (GLP) and Good Manufacturing Practice, (GMP) requirements required by Aptahem.
This collaboration will enable the implementation of a thorough evaluation of APTA-1’s biological effects. It will, among other things, help to clarify the anti-inflammatory properties of APTA-1. It is these anti-inflammatory properties that are central to the successful treatment of diseases like stroke.
Red Glead is working on the formulation and stability for Aptahem’s lead candidate drug, Apta-1.
We help our customers translate preclinical projects into clinical success and offer services in three main areas: 1) strategic planning, 2) preclinical pharmacology and 3) personalized medicine
Truly Labs AB is a pre-clinical CRO that provides customized in vitro and in vivo services.
Aptahem and Truly collaborate on the preclinical drug development and safety programme for Apta-1.
Axolabs is developing a bioanalytical method for analyzing Aptahem’s lead candidate Apta-1.
Accelera is performing the non-clinical toxicology program on Aptahem’s lead candidate Apta-1.
Hooke Laboratories work together with Aptahem in in vivo animal models.